ZLC491

Overview

ZLC491 is an orally active PROTAC degrader that selectively targets CDK12/CDK13 and exhibits certain oral bioavailability. ZLC491 induces cereblon- and proteasome-dependent selective degradation of CDK12 and CDK13 . ZLC491 inhibits the transcription and expression of long genes, and mainly acts on a subset of DNA damage response genes. ZLC491 inhibits the proliferation of various triple-negative breast cancer cells. ZLC491 can be used in research related to triple-negative breast cancer . (Pink: CDK12 and CDK13 ligand ( HY-168163 ); Blue: Cereblon ligand ( HY-W093272 ); Black: linker ( HY-W904851 )).

Application

Products | Products > Disease Areas > Blood Disease | Products > Disease Areas > Triple-Negative Breast Cancer | Products > Disease Areas > Cancer | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Breast Cancer | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Signaling Pathways > PROTAC | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > PROTACs | Products > Signaling Pathways > CDK

Product Information

• Catalog No.: HY-168162
• CAS No.: 3053716-46-1
• Molecular Formula: C48H51FN10O5
• Molecular Weight: 866.98
• Purity: 98.51%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 2.5 mg/mL (2.88 mM); Clear solution
• Availability: In-stock

Source

Original product source